• 64. Correspondence between negative symptoms and potential sources of secondary negative symptoms over time. Farreny, A, Savill, M y Priebe, S. 2018, Eur Arch Psychiatry Clin Neurosci, págs. 268(6):603-609. • 65. Neurochemical and neural mechanisms of positive and negative symptoms in schizophrenia. Pickar, D, Litman, R y Konocki, P. 1990, Mod Probl Pharmacopsychiatry, págs. 24:124-51. • 66. Virtual reality assessment of functional capacity in people with Schizophrenia: Associations with reduced emotional experience and prediction of functional outcomes. Harvey, P, y otros. 2019, Psychiatry Res, págs. 277:58-63. • 67. Negative symptoms in depression. Chaturvedi, S y Sarmukaddam, S. 1985, Indian J Psychiatry., págs. 27(2):139-44. • 68. Schneiderian versus Bleulerian Schizophrenia and Basic Symptoms. Peralta, V y Cuesta, M. 1991, Psychopathology, págs. 24: 151-157. • 69. OMS. Clasificación Estadística Internacional de Enfermedades y Problemas Relacionados con la Salud. Ginebra: Organización Mundial de la Salud, 1992. • 70. Clasificación Internacional y Estadística de Enfermedades y Problemas Relacionados con la Salud. Ginebra: Organización Mundial de la Salud, 2019. • 71. The specificity of Bleulerian and Schneiderian symptoms: a critical reevaluation. Andreasen, N y Akiskal, H. 1983, Psychiatr Clin NortAm, págs. 41-54. • 72. Negative Symptoms in Schizophrenia and Depression. Chaturvedi, S, y otros. 1985, Indian Journal o Psychiatry, págs. 237-241. • 73. Negative and positive symptoms in schizophrenia and depression: a followup. Pogue-Geile, M y Harrow, M. 1984, Schizophr Bull., págs. 10(3):371-87. • 74. The Scale for the Assessment of Negative Symptoms (SANS): conceptual and theoretical foundations. Andreasen, N. 1989, Br J Psychiatry Suppl., págs. (7):49-58. • 75. The Schedule for the Deficit syndrome: an instrument for research in schizophrenia. Kirkpatrick, B, y otros. 1989, Psychiatry Res., págs. 30(2):119-23. • 76. Deficit and nondeficit forms of schizophrenia: the concept. Carpenter, W, Heinrichs, D y Wagman, A. 1988, Am J Psychiatry, págs. 145(5):578-83. • 77. The positive and negative syndrome scale (PANSS) for schizophrenia. Kay, S, Fiszbein, A y Opler, L. 1987, Schizophr Bull., págs. 13(2):261-76. • 78. Using the Positive and Negative Syndrome Scale (PANSS) to Define Different Domains of Negative Symptoms: Prediction of Everyday Functioning by Impairments in Emotional Expression and Emotional Experience. Harvey, P, Khan, A y Keefe, R. 2017, Innov Clin Neurosci, págs. 18-22. • 79. A depression rating scale for schizophrenics. Addington, D, Addington, J y Schissel, B. 1990, Schizophr Res, págs. 3(4):247-51. • 80. An investigation of the postpsychotic depressive syndrome. McGlashan, T y Carpenter, W. 1976, Am J Psychiatry., págs. 133(1):14-9. • 81. Correspondence between negative symptoms and potential sources of secondary negative symptoms over time. Farreny, A, Savill, M y Priebe, S. 2018, Eur Arch Psychiatry Clin Neurosci., págs. 268(6):603-609. • 82. Gender-specific associations of depression with positive and negative symptoms in acute schizophrenia. Müller, M. 2007, Prog Neuropsychopharmacol Biol Psychiatry, págs. 31(5):1095-100. • 83. Effects of age of onset on clinical characteristics in schizophrenia spectrum disorders. Kao, Y yLiu, Y. 2010, BMC Psychiatry, págs. 10-63. • 84. Age at onset and the outcomes of schizophrenia: A systematic review and meta-analysis. Immonen, J, Jääskeläinen, E y Korpela, H. 2017, Early Interv Psychiatry., págs. 11(6):453-460. • 85. Duration of untreated illness as a key to early intervention in schizophrenia: A review. Murru, A y Carpiniello, B. 2018, Neurosci Lett., págs. 669:59-67. • 86. Duration of untreated psychosis and negative symptoms--a systematic review and meta-analysis of individual patient data. Boonstra, N, y otros. 2012, Schizophr Res, págs. 12-9. • 87. Negative symptoms in schizophrenia: a review. Mäkinen, J, y otros. 2008, Nord J Psychiatry, págs. 62(5):334-41. • 88. Negative symptoms and the early course of schizophrenia. Husted, J, Beiser, M y Iacono, W. 1992, Psychiatry Res., págs. 43(3):215-22. • 89. Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Perkins, D, y otros. 2005, Am J Psychiatry, págs. 1785-804. • 90. Duration of untreated psychosis as predictor of long-term outcome in schizophrenia: systematic review and meta-analysis. Penttilä, M, Jääskeläinen, E y Hirvonen, N. 2014, Br J Psychiatry., págs. 88-94. • 91. Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. Volkow, N, y otros. 2009, Jama, págs. 301(11):1148-54. • 92. Amphetamines for schizophrenia. Nolte, S, Wong, D y Lachford, G. 2004, Cochrane Database Syst Rev., pág. (4):CD004964. • 93. Group II metabotropic glutamate receptor agonists and positive allosteric modulators as novel treatments for schizophrenia. Fell, M, y otros. 2012, Neuropharmacology, págs. 62(3):1473-83. • 94. Epigenetic Alterations in Prenatal Stress Mice as an Endophenotype Model for Schizophrenia: Role of Metabotropic Glutamate 2/3 Receptors. Matrisciano, F, y otros. 2018, Front Mol Neurosci, pág. 11:423. • 95. Clozapine augmented with glutamate modulators in refractory schizophrenia: a review and metaanalysis. Veerman, S, y otros. 2014, Pharmacopsychiatry., págs. 47(6):185-94. • 96. The glutamate hypothesis: a pathogenic pathway from which pharmacological interventions have emerged. Veerman, S, Schulte, P y de Haan, L. 2014, Pharmacopsychiatry., págs. 47(4-5):121-30. • 97. Efficacy for Psychopathology and Body Weight and Safety of Topiramate-Antipsychotic Cotreatment in Patients With Schizophrenia Spectrum Disorders: Results From a Meta-Analysis of Randomized Controlled Trials. Correll, C, y otros. 2016, J Clin Psychiatry, págs. 746-56. • 98. Efficacy and safety of adjunctive topiramate for schizophrenia: a meta-analysis of randomized controlled trials. Zheng, W, y otros. 2016, Acta Psychiatr Scand., págs. 134(5):385-398. • 99. Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis. Singh, S, y otros. 2010, Br J Psychiatry, págs. 197(3):174-9. • 100. Efficacy and Safety of Antidepressants Added to Antipsychotics for Schizophrenia: A Systematic Review and Meta-Analysis. Helfer, B, 12 // EDITORIAL SCIENS
Psiquiatría N° 44 | Octubre 2021 y otros. Am J Psychiatry, 2016, págs. 173(9):876-86. • 101. Randomized Controlled Trials of Add-On Antidepressants in Schizophrenia. Terevnikov, V, Joffe, G y Stenberg , J. 2015, Int J Neuropsychopharmacol., pág. 18(9). • 102. Non-glutamatergic clozapine augmentation strategies: a review and meta-analysis. Veerman, S, y otros. 2014, Pharmacopsychiatry, págs. ;47(7):231-8. • 103. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Leucht, S, y otros. 2009, Mol Psychiatry., págs. 14(4):429-47. • 104. Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. Zhang, J, y otros. 2013, Int J Neuropsychopharmacol, págs. 16(6):1205-18. • 105. Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis. Galling, B, y otros. 2017, World Psychiatry., págs. 16(1):77-89. • 106. Efficacy and Safety of Adjunctive Aripiprazole in Schizophrenia: Meta-Analysis of Randomized Controlled Trials. W, y otros. 2016, J Clin Psychopharmacol, págs. 36(6):628-636. • 107. Efficacy and safety of aripiprazole augmentation of clozapine in schizophrenia: a systematic review and meta-analysis of randomized-controlled trials. Srisurapanont, M, y otros. 2015, J Psychiatr Res., págs. 62:38-47. • 108. Subjective experience and striatal dopamine D (2) receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone. de Haan, L, y otros. 2000, Am J Psychiatry., págs. 157(6):1019-20. • 109. Prevalence of neuroleptic-induced movement disorders: an 8-year follow-up study in chronic schizophrenia inpatients. Parksepp, M, y otros. 2016, Nord J Psychiatry, págs. 498-502. • 110. A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone. Corponi F, Fabbri C, Bitter I, Montgomery S, Vieta E, Kasper S, Pallanti S, Serretti A. Novel antipsychotics specificity profile: Eur Neuropsychopharmacol. 2019 Sep;29(9):971-985. • 111. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, Arndt T, Bäckers L, Rothe P, Cipriani A, Davis J, Salanti G, Leucht S. Lancet. 2019 Sep 14;394(10202):939-951. • 112. The efficacy of cariprazine in negative symptoms of schizophrenia: Post hoc analyses of PANSS individual items and PANSS-derived factors. Fleischhacker W, Galderisi S, Laszlovszky I, Szatmári B, Barabássy Á, Acsai K, Szalai E, Harsányi J, Earley W, Patel M, Németh G. Eur Psychiatry. 2019 May;58:1-9. • 113. Negative Symptoms in Schizophrenia: A Review and Clinical Guide for Recognition, Assessment, and Treatment. Correll CU, Schooler NR. Neuropsychiatr Dis Treat.33 2020 Feb 21;16:519-534. doi: 10.2147/NDT.S225643. PMID: 32110026; PMCID: PMC7041437. • 114. EPA guidance on treatment of negative symptoms in schizophrenia. Galderisi S, Kaiser S, Bitter I, Nordentoft M, Mucci A, Sabé M, Giordano GM, Nielsen MØ, Glenthøj LB, Pezzella P, Falkai P, Dollfus S, Gaebel W. Eur Psychiatry. 2021 Mar 17;64(1):e21. • 115. Cognitive model and cognitive behavior therapy for schizophrenia: an overview. Sarin, F y Wallin, L. 2014, Nord J Psychiatry., págs. 68(3):145-53. • 116. Psychological and psychosocial interventions for negative symptoms in psychosis: systematic review and meta-analysis. Lutgens, D, Gariepy, G y Malla, A. 2017, Br J Psychiatry, págs. 210:324-32. • 117. Motivational deficits and netaive symptoms in schizophrenia: concepts and assessments. Reddy, L, Horan, W y Green, M. 2016, Curr Topics Behav Neurosci, págs. 27:357-73. • 118. Effectiveness of integrated psychological therapy (IPT) for schizophrenia patients: a research update. Roder V, V, Mueller D, D y Schmidt S, S. 2011, Schizophr Bull., págs. S71-9. • 119. Mindfulness interventions for psychosis: a meta-analysis. Khoury B, B, y otros. 2013, Schizophr Res., págs. 150(1):176-84. • 120. Yoga versus standard care for schizophrenia. Broderick J, J, y otros. 2015, Cochrane Database Syst Rev, pág. (10):CD010554. • 121. Exercise improves clinical symptoms, quality of life, global functioning, and depressions in schizophrenia: a systematic review and meta-analysis. Dauwan, M, Begemann, M y Heringa, S. 2016, Schizophr Bull, págs. 42: 588-99. • 122. Yoga as part of a package of care versus non-standard care for schizophrenia. Broderick J, J y Vancampfort, D. 2019, Cochrane Database Syst Rev., pág. 4:CD012807. • 123. Repetitive transcranial magnetic stimulation as an adjunctive treatment for negative symptoms and cognitive impairment in patients with schizophrenia: a randomized, double-blind, sham-controlled trial. Zhuo, K, y otros. 2019, Neuropsychiatr Dis Treat., págs. 15:1141-1150. EDITORIAL SCIENS // 13
Loading...
Loading...